SSA
ANIK icon

Schonfeld Strategic Advisors’s Anika Therapeutics ANIK Stock Holding History

Schonfeld Strategic Advisors’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$160K Buy
+11,021
New +$128K ﹤0.01% 1799
2020
Q4 		– Sell
-9,906
Closed -$350K – 1548
2020
Q3 		$350K Buy
+9,906
New +$358K 0.01% 1038
2020
Q2 		– Sell
-10,424
Closed -$301K – 1223
2020
Q1 		$301K Buy
+10,424
New +$422K 0.02% 750
2018
Q3 		– Sell
-11,300
Closed -$361K – 790
2018
Q2 		$361K Buy
+11,300
New +$465K 0.02% 595

Other funds holding ANIK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
CM
Capital Management Glen Allen, Virginia $585M AUM 5.18% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Schonfeld Strategic Advisors's ANIK Position: Q1 2026 in Review

Schonfeld Strategic Advisors opened a new position in Anika Therapeutics (ANIK) in Q1 2026: 11,021 shares worth $160K. The stake represents ﹤0.01% of the portfolio and ranks #1799 among its holdings. This is a return to the name: Schonfeld Strategic Advisors previously reported a position in ANIK as recently as Q3 2020.

Schonfeld Strategic Advisors first reported a position in ANIK in Q2 2018 and has held it in 4 quarters since. The position peaked at $361K in Q2 2018. 130 funds tracked by Wall St. Rank hold ANIK as of Q1 2026.

  • Schonfeld Strategic Advisors held 11,021 shares of Anika Therapeutics worth $160K as of Q1 2026.
  • Anika Therapeutics was a new Schonfeld Strategic Advisors position in Q1 2026.
  • Anika Therapeutics made up ﹤0.01% of Schonfeld Strategic Advisors's portfolio in Q1 2026, its #1799 holding.
  • Schonfeld Strategic Advisors first reported a position in Anika Therapeutics in Q2 2018 and has held it in 4 quarters since.
  • Schonfeld Strategic Advisors's Anika Therapeutics position peaked at $361K in Q2 2018.
  • 130 funds tracked by Wall St. Rank held Anika Therapeutics as of Q1 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2026, filed 15 May 2026.